Summary: Adoptive cell therapy of metastatic melanoma with autologous tumor infiltrating lymphocytes (TIL) is clinically effective, but TIL production can be challenging. Here we describe a simplified method for initial TIL culture and rapid expansion in gas-permeable flasks. TIL were initially cultured from tumor digests and fragments in 40 mL capacity flasks with a 10 cm 2 gas-permeable silicone bottom, G-Rex10. A TIL rapid expansion protocol (REP) was developed using 500 mL capacity flasks with a 100 cm 2 gas-permeable silicone bottom, G-Rex100. TIL growth was successfully initiated in G-Rex10 flasks from tumor digests from 13 of 14 patients and from tumor fragments in all 11 tumor samples tested. TIL could then be expanded to 8-10Â10 9 cells in a 2-step REP that began by seeding 5Â 10 6 TIL into a G-Rex100 flask, followed by expansion at day 7 into 3 G-Rex100 flasks. To obtain the 30-60Â10 9 cells used for patient treatment, we seeded 6 G-Rex100 flasks with 5Â10 6 cells and expanded into 18 G-Rex100 flasks. Large-scale TIL REP in gaspermeable flasks requires approximately 9-10 L of media, about 3-4 times less than other methods. In conclusion, TIL initiation and REP in gas-permeable G-Rex flasks require fewer total vessels, less media, less incubator space, and less labor than initiation and REP in 24-well plates, tissue culture flasks, and bags. TIL culture in G-Rex flasks will facilitate the production of TIL at the numbers required for patient treatment at most cell processing laboratories.
A doptive cell therapy with tumor infiltrating lymphocytes (TIL) following host lymphodepletion leads to objective response rates of 50%-70% patients with metastatic melanoma. [1] [2] [3] [4] TIL therapy involves culturing cytotoxic T cells from dissected tumor fragments or enzymatically digested tumor and expanding the cells by serial passage. 3, 5 Patients enrolled in initial clinical trials received an average dose of 60Â10 9 TIL. Because generating these large quantities of cells over a short period of time is labor intensive and requires a skilled laboratory staff, it is desirable to simplify TIL production.
Traditionally, TIL were grown from melanoma fragments in microcultures with interleukin-2 (IL-2), selected for tumor-specific reactivity and were then rapidly expanded. Recent studies evaluated the means for the growth of TIL that enabled the administration of cells with shorter culture times derived from single cell suspensions of tumors. 6, 7 These "Young TIL" had properties that were associated with improved in vivo persistence and response rates including long telomeres and increased expression of CD27 and CD28. [8] [9] [10] [11] [12] Production of young TIL involves initial TIL culture from dissected tumor fragments or digested tumor in media containing human AB serum and IL-2 in 24-well plates, conditions that favor the growth of TIL cells over tumor and other cells. If after approximately 2-4 weeks in culture an adequate quantity of TIL ranging from 50 to 200Â10 6 can be obtained, a portion of these TIL are then further expanded 500-2000-fold over 2 weeks to obtain 30-60Â10 9 TIL. This rapid expansion protocol (REP) for TIL typically is performed in tissue culture flasks and gas-permeable bags. The first step of REP involves the coculture of TIL with irradiated autologous or allogeneic peripheral blood mononuclear cells (PBMCs) as feeders in T-175 flasks in media with IL-2 and anti-CD3 for 7 days. The cells are then transferred to gaspermeable bags and are cultured for an additional 7 days. Because the optimal density of cells cultured in bags is approximately 0.5-2Â10 6 cells/mL, the final volume of the culture is 30-60 L. At the end of the culture period the cells FIGURE 1. G-Rex flasks. Three types of flasks with silicone gaspermeable bottoms were used in these studies. The G-Rex10 flask has a 10 cm 2 silicon bottom and holds approximately 40 mL (left). The G-Rex100 flask has a 100 cm 2 silicon bottom and holds approximately 500 mL (center). The G-Rex100L has the same 100 cm 2 silicon bottom as the G-Rex100 flask but it holds approximately 2000 mL (right). must be concentrated, washed, and resuspended in a volume that can be administered intravenously over 1-2 hours.
Although the production of young TIL is simpler than previous described methods, initial TIL growth and REP using 24-well plates, tissue culture flasks, and gas-permeable bags can be challenging and these procedures are not well suited for cell growth and expansion under the current good manufacturing practice conditions that are required for phase III clinical trials. Initial TIL culture normally involves the growth of TIL from tumors in 24-well plates that is an "open" system and susceptible to microbial contamination. There are also several limitations to TIL REP in tissue culture flasks and bags. First, the initial step of REP in tissue culture flasks is also an open system that further increases the risk of microbial contamination during culture. Second, numerous containers are used that makes the process labor intensive and that also increases the risk of microbial contamination. Third, the final culture volume is large and requires considerable incubator capacity, specialized instruments for concentrating and washing the cells, and large quantities of culture media and additives. Fourth, the process requires a highly trained and highly skilled staff.
The goal of this study was to develop an initial TIL culture and REP process that can be used by most cell processing laboratories. We found that both initial TIL culture and REP could be performed in gas-permeable flasks using far less media, reagents, and total number of containers than previously described methods.
MATERIALS AND METHODS

Initial TIL Culture
Patients were entered into clinical protocols and signed informed consents that were approved by the Institutional Review Board of the National Cancer Institute before tumor resection. TIL were initially cultured from enzymatic tumor digests and tumor fragments (1-8 mm 3 ) produced by sharp dissection. Tumor digests were generated by incubation in enzyme media (RPMI 1640, 2 mM GlutaMAX, 10 mg/mL gentamicin, 30 U/mL DNase, and 1.0 mg/mL collagenase) followed by mechanical dissociation (GentleMACS, Miltenyi Biotec, Auburn, CA). Immediately after placing the tumor in enzyme media, it was mechanically dissociated for approximately 1 minute. The solution was then incubated for 30 minutes at 371C in 5% CO 2 and it was then mechanically disrupted again for approximately 1 minute. After being incubated again for 30 minutes at 371C in 5% CO 2 , the tumor was mechanically disrupted a third time for approximately 1 minute. If after the third mechanical disruption, large pieces of tissue were present, 1 or 2 additional mechanical dissociations were applied to the sample, with or without 30 additional minutes of incubation at 371C in 5% CO 2 . At the end of the final incubation if the cell suspension contained a large number of red blood cells or dead cells, a density gradient separation using Ficoll was performed to remove these cells.
When TIL cultures were initiated in 24-well plates (Costar 24-well cell culture cluster, flat bottom; Corning Incorporated, Corning, NY), each well was seeded with 1Â 10 6 tumor digest cells or one tumor fragment approximately 1-8 mm 3 in size in 2 mL of complete medium (CM) with IL-2 (6000 IU/mL; Chiron Corp., Emeryville, CA). CM consisted (Fig. 1) , each flask was loaded with 10-40Â 10 6 viable tumor digest cells or 5-30 tumor fragments in 10-40 mL of CM with IL-2. Both the G-Rex10 and 24-well plates were incubated in a humidified incubator at 371C in 5% CO 2 and 5 days after culture initiation, half the media was removed and replaced with fresh CM and IL-2 and after day 5, half the media was changed every 2-3 days.
TIL REP
REP of TIL was performed using T-175 flasks and gas-permeable bags as previously described 8, 13 or gas-permeable G-Rex flasks. For TIL REP in T-175 flasks, 1 Â10 6 TIL suspended in 150 mL of media was added to each T-175 flask. The TIL were cultured with irradiated (50 Gy) allogeneic PBMC as "feeder" cells at a ratio of 1 to 100 and the cells were cultured in a 1 to 1 mixture of CM and AIM-V medium (50/50 medium), supplemented with 3000 IU/mL of IL-2 and 30 ng/mL of anti-CD3. The T-175 flasks were incubated at 371C in 5% CO 2 . Half the media was changed on day 5 using 50/50 medium with 3000 IU/mL of IL-2. On day 7, cells from 2 T-175 flasks were combined in a 3 L bag and 300 mL of AIM-V with 5% human AB serum and 3000 IU/mL of IL-2 was added to the 300 mL of TIL suspension. The number of cells in each bag was counted every day or 2 and fresh media was added to keep the cell count between 0.5 and 2.0 Â10 6 cells/mL. For TIL REP in 500 mL capacity flasks with 100 cm 2 gas-permeable silicon bottoms (G-Rex100,Wilson Wolf) (Fig. 1) , 5Â10 6 or 10Â10 6 TIL were cultured with irradiated allogeneic PBMC at a ratio of 1 to 100 in 400 mL of 50/50 medium, supplemented with 3000 IU/mL of IL-2 and 30 ng/ mL of anti-CD3. The G-Rex100 flasks were incubated at 371C in 5% CO 2 . On day 5, 250 mL of supernatant was removed and placed into centrifuge bottles and centrifuged at 1500 rpm (491g) for 10 minutes. The TIL pellets were resuspended with 150 mL of fresh 50/50 medium with 3000 IU/ mL of IL-2 and added back to the original G-Rex100 flasks. When TIL were expanded serially in G-Rex100 flasks, on day 7 the TIL in each G-Rex100 were suspended in the 300 mL of media present in each flask and the cell suspension was divided into three 100 mL aliquots that were used to seed 3 G-Rex100 flasks. Then 150 mL of AIM-V with 5% human AB serum and 3000 IU/mL of IL-2 was added to each flask. The G-Rex100 flasks were incubated at 371C in 5% CO 2 and after 4 days 150 mL of AIM-V with 3000 IU/mL of IL-2 was added to each G-Rex100 flask. The cells were harvested on day 14 of culture.
Cell Counts, Viability, Flow Cytometry
The expression of CD3, CD4, CD8, and CD56 was measured by flow cytometry with antibodies from BD Biosciences (BD Biosciences, San Jose, CA) using a FACSCanto flow cytometer (BD Biosciences). The cells were counted manually using a disposable c-chip hemocytometer (VWR, Batavia, IL) and viability was assessed using trypan blue staining.
Cytokine Release Assays
TIL were evaluated for interferon-g (IFN-g) secretion in response to stimulation either with OKT3 or coculture with autologous tumor digest. For OKT3 stimulation, TIL were washed extensively, and duplicate wells were prepared with 1Â 10 5 cells in 0.2 mL CM in 96-well flat-bottom plates precoated with 0.1 or 1.0 mg/mL of OKT3 diluted in phosphate-buffered saline. After overnight incubation, the supernatants were harvested and IFN-g in the supernatant was measured by ELISA (Pierce/Endogen, Woburn, MA). For the coculture assay, 1Â 10 5 TIL cells were placed into a 96-well plate with autologous tumor cells. (1:1 ratio) After a 24-hour incubation, supernatants were harvested and IFN-g release was quantified by ELISA.
Statistical Analysis
Values in the text are mean ± 1 SEM unless otherwise indicated. Groups were compared using paired T tests.
RESULTS
Initial TIL Culture
We compared the growth of TIL from tumors using gaspermeable flasks with a 40 mL capacity and 10 cm 2 gaspermeable silicone bottom (G-Rex10) with growth in 24-well plates. Fourteen melanoma samples were tested: 9 consisting of freshly prepared tumor digests and 5 thawed samples from previously frozen tumor digests. Except for 1 fresh sample (#3522), the ratio of harvested TIL to initially seeded cells at days 17-29 was similar to or better in the G-Rex10 flasks than in the 24-well plates ( Table 1) . The viability and percentage of cells expressing CD3 and CD8 grown in the G-Rex10 flasks and 24-well plates were similar (Table 1) . TIL were obtained from 13 of the 14 samples. We could not culture TIL in either the G-Rex10 or 24-well plates from frozen tumor digest from patient 2653. These results suggest that TIL growth in G-Rex10 flasks is comparable with that in 24-well plates. We compared IFN-g production by TIL cultured in G-Rex10 flasks with those cultured in 24-well plates. IFN-g production after stimulation with autologous tumor by TIL from 4 patients cultured in both types of vessels was similar (Table 2) .
We next compared the growth of TIL in G-Rex10 flasks or 24-well plates from tumor fragments. For each tumor sample, fragments approximately 1-8 mm 3 in size were seeded into 24-well plates at 1 piece per well and into G-Rex10 flasks at 5, 10, 20, or 30 pieces per flask. A total of 11 tumor samples collected from 9 patients were tested; 3 samples were from 1 patient, but they were from different metastatic tumors. TIL could be grown from tumor fragments from all 11 samples in both the G-Rex10 flasks and 24-well plates, but after 7-23 days in culture greater quantities of TIL were obtained from the G-Rex10 flasks. The head-to-head comparison of culturing 10 fragments in the 2 types of vessels showed that TIL yields from G-Rex10 flasks were consistently higher than those from 24-well plates ( Fig. 2A) . The optimal numbers of fragments seeded into each G-Rex10 flasks was further assessed. The quantities of TIL obtained per tumor fragment decreased as the number of pieces added to each G-Rex10 flask increased (Fig. 2B) , however, total TIL yield was higher as more fragments were cultured in the G-Rex10 flasks until 20 or more tumor fragments were cultured in each G-Rex10 flask (Fig. 2C) . The viability of TIL obtained from G-Rex10 flasks was similar to that of TIL obtained from 24-well plates (96.6 ± 0.6% vs. 95.3 ± 0.8%) as was the proportion of TIL expressing CD3 and CD8 (67.8 ± 7.2% vs. 63.3 ± 7.7%). TIL were also obtained from 3 of the 11 samples by the culture of mechanically dissociated samples in G-Rex10 flasks, but greater yields were obtained using tumor fragments as the starting material (data not shown). It is not certain why the number of TIL produced per fragment decreased when more than 10 fragments were added; however, this may be related to the quantity of nutrients and oxygen available or release of suppressive factors by the tumor cells.
Comparison of T-175 and G-Rex100 Flasks for the First Step of TIL REP
The first step in TIL REP has traditionally been performed in T-175 flasks. We compared the expansion of TIL in T-175 flasks to expansion in G-Rex100 flasks. We first assessed the kinetics of TIL growth in gas-permeable flasks. TIL from 1 patient were cultured in G-Rex100 flasks seeded at a density of 5Â 10 6 and 10Â10 6 cells per flask. The cells were counted daily after day 6. On day 6, the number of cells in the G-Rex100 flask seeded at 5Â 10 6 cells was 255Â 10 6 cells and at 10Â10 6 cells was 300Â 10 6 cells. The quantity of TIL in G-Rex100 flasks seeded at each cell density increased steadily until day 9, but there was little increase in cell counts between days 9 and 10. After 10 days, 906Â10 6 cells were harvested from the G-Rex100 flask seeded with 5Â10
6 TIL and 1050Â10
6 cells from G-Rex100 flask seeded with 10Â10
6 TIL (Fig. 3) . Although TIL expanded well for 9 days, to keep the G-Rex100 flask expansion process similar to REP in T-flasks and gas-permeable bags where TIL are transferred from T-flasks to bags on day 7, for further studies we focused on TIL expansion in the G-Rex100 flasks for 7 days.
Next, we identified the optimal seeding density for REP in G-Rex100 flasks. We compared the expansion of TIL from 4 patients over 7 days in G-Rex100 flasks seeded with 5Â10 6 and 10Â 10 6 cells and compared this with TIL expansion in T-175 flasks. After 7 days of culture in T-175 flasks, the number of TIL increased to 206 ± 51Â 10 6 cells that represented an expansion of 167 ± 37-fold (Table 3 ). The culture of TIL from the same 4 patients in G-Rex100 flasks seeded with 5Â 10 6 cells resulted in the production of 877 ± 182Â10 6 cells that represented an expansion of 176 ± 36-fold. The culture of TIL from 2 of the 4 patients in G-Rex100 flasks seeded with 10Â 10 6 cells resulted in the production of 980 ± 290Â10 6 cells that represented an expansion of 98 ± 29-fold. The viability and proportion of cells that expressed CD3 and CD8 were similar among those produced under 3 different conditions (Table 3 ). These results suggested that the performance of G-Rex100 flasks seeded at the lower seeding density was comparable with that of the T-175 flasks. Because the 7-day culture of TIL in G-Rex100 flasks seeded with 10Â10 6 cells did not produce a significantly greater number of cells than the G-Rex100 flasks seeded with 5Â 10 6 cells, the lower seeding density was preferable.
TIL REP Using Serial Culture in G-Rex100 Flasks
Because the maximum number of TIL present in 1 G-Rex100 flask reached a plateau after approximately 6 TIL were seeded into a G-Rex100 and a G-Rex100L gas-permeable flask. For expansion in both types of flasks, the TIL were cultured with irradiated peripheral blood mononuclear cells at a TIL to feeder cell ratio of 1 to 100 and the cells were cultured in a 1 to 1 mixture of CM and AIM-V medium, supplemented with interleukin-2 (3000 IU/mL) and anti-CD3 (30 ng/mL). After 7 days, the TIL in the G-Rex100 flask were split equally into 3 and the culture was continued in the 3 G-Rex100 flasks. The TIL grown in the G-Rex100L flask were also divided after 7 days, but they were split in half and cultured in 2 G-Rex100L flasks. The cells in both types of containers were maintained in culture for 17 days. TIL from 2 patients were tested, patients 2998 (A) and 2761 (B). Growth of cells in the G-Rex100 flasks are shown by the solid lines and squares, the G-Rex100L flasks by the dashed lines and triangles. TIL for REP was prepared by growth in 24-well plates from fresh tumor digests. TIL indicates tumor infiltrating lymphocyte. 9 days, the production of adequate quantities of TIL for clinical therapy required the splitting of cells during REP and transferring the cells into multiple G-Rex flasks for further culture. We tested TIL REP by serial culture in G-Rex flasks. In addition to the G-Rex100 flask, there is another type of gas-permeable flask that is commercially available for the large-scale cell expansion: the G-Rex100L. The G-Rex100L has the same gas-permeable surface area on the silicone bottom of the flask as the G-Rex100, but the G-Rex100L is taller (Fig. 1) . As a result the media capacity of the G-Rex100L flask is approximately 2000 mL compared with approximately 500 mL for the G-Rex100. We compared TIL expansion using these 2 types of flasks. TIL were initially seeded at a density of 5Â10 6 cells for both the G-Rex100 and G-Rex100L flasks and were cultured for 7 days in both types of flasks. After 7 days, the cells from the G-Rex100 flask were split into 3 equal parts, and seeded into 3 G-Rex100 flasks and the cells from the G-Rex100L flask were split into 2 equal parts, seeded into 2 G-Rex100L flasks. The TIL were cultured for an additional 7 days in the G-Rex100 and G-Rex100L flasks.
The expansion of TIL from 2 patients was compared in the G-Rex100 and G-Rex100L flasks. Both patients' TIL growth slowed after 13 or 14 days (Fig. 4) . The total number of cells produced after 14 days by culture in the 3 G-Rex100 flasks and the 2 G-Rex100L flasks was similar for 1 patient but was greater in the G-Rex100 flask for the second. Because a similar volume of media is required to produce a similar number of cells in the G-Rex100 and in the G-Rex100L flasks and since the G-Rex100 flasks are easier to handle, we elected to expand TIL initially in 1 G-Rex100 flask followed by expansion in 3 G-Rex100 flasks.
We next tested the consistency of serial TIL expansion in G-Rex100 flasks using cells from 14 patients (Fig. 5) . Initially, 5 Â10 6 TIL were seeded into a G-Rex100 flask and the cells were cultured for 7 days. They were then split into 3 equal parts, seeded into 3 G-Rex100 flasks. After 14 days in culture, 8.60 ± 0.75 Â 10 9 TIL with a range of 2.24 Â10 9 to 12.8 Â10 9 were produced (Fig. 5) . The number of TIL produced after 14 days was similar for 12 patients, but lower for 2 others. When the 2 patients with the lowest overall TIL expansion were excluded, the mean quantity of TIL produced was 9.55 Â 10 9 cells per original G-Rex100 flask. The mean cell concentration in G-Rex100 flasks at the end of the culture was 7.95 Â10 6 cells/mL. The IFN-g release from TIL produced by G-Rex100 REP and T-175 flask/bag REP was compared. TIL samples produced by both REP methods using the same tumor samples from 4 patients were tested. After stimulation by anti-CD3, IFN-g production by TIL expanded in G-Rex100 flasks was similar to that of TIL expanded in T-175 flasks and bags (Table 4) .
These results suggested that 20-30Â10 9 TIL could be produced by the initial culture of 15 Â10 6 TIL in 3 G-Rex100 flasks for 7 days followed by a second 7-day culture in 9 G-Rex100 flasks (Fig. 6 ). To test this "full-scale" G-Rex100 REP, 15Â10 6 TIL from 1 patient were divided among 3 G-Rex100 flasks, A, B, and C. After 7 days in culture, the TIL in each flask were split into 3 equal parts, seeded into 3 G-Rex100 flasks, and cultured for an additional 7 days. The mean number of TIL harvested from each of the 3 G-Rex100 flasks used for initial expansion was 875 ± 30.8Â10 6 and ranged from 849Â10 6 to 909Â10 6 TIL and the mean number harvested from each of the 9 G-Rex100 flasks used for the secondary expansion was 2.63 ± 0.03Â10 9 and ranged from 2.55Â10 9 to 2.76 Â10 9 TIL (Table 5 ). The total TIL collection yield was 23.6Â10 9 and 21.0Â10 9 remained after washing the cells. Their viability was 96% and 69% of the cells expressed CD3 and CD8.
Clinical Scale TIL Initiation and REP in G-Rex Flasks
We next tested clinical scale TIL production using tumor fragments from 3 patients by initially culturing TIL wValues are IFN-g (pg/mL) detected in duplicate wells measured by ELISA (see the Materials and methods section).
IFN indicates interferon; TIL, tumor infiltrating lymphocyte.
FIGURE 5. Consistency of serial TIL culture in G-Rex100 gaspermeable flasks for rapid expansion. TIL from 14 patients were expanded over 14 days in G-Rex100 flasks using a 2-step process.
For the first step of TIL REP a G-Rex100 flask was seeded with 5Â 10 6 TIL and irradiated PBMCs at a TIL to feeder cell ratio of 1 to 100 and the cells were cultured in a 1 to 1 mixture of CM and AIM-V medium, supplemented with IL-2 (3000 IU/mL) and anti-CD3 (30 ng/mL). After 7 days of culture, the TIL were harvested and divided. One third of the cells were cultured 7 more days in a second G-Rex100 flask. The total number of cells that would have been produced using 3 G-Rex100 flasks for the second step of expansion is shown. TIL for REP were prepared by growth in 24-well plates from fresh tumor digests from 8 patients and by growth in 24-well plates from frozen tumor digests from 6 patients (samples 1812, 3282, 2976, 3020, 2998, and 2761). REP indicates rapid expansion protocol; TIL, tumor infiltrating lymphocyte.
in G-Rex10 flasks followed by REP in G-Rex100 flasks. For each patient, 6 G-Rex10 flasks were seeded with 5 tumor fragments and after 14-15 days 5 Â 10 6 TIL from each G-Rex10 flask were seeded into 1 G-Rex100 flask. After 7 days, TIL from each G-Rex100 flask were split into 3 G-Rex100 flasks and after an additional 7 days in culture TIL were harvested from the 18 G-Rex100 flasks. For 2 patients, 3613 and 3618, enough TIL could be harvested from each of the 6 G-Rex10 flasks for TIL REP in a G-Rex100 flask. The quantity of TIL harvested from each of the G-Rex10 flasks ranged from 47.5 to 97.8 Â10 6 cells for patient 3613 and 24.6 to 64.2Â10 6 for patient 3618 (Table 6 ). For patient 3625, sufficient quantities of TIL were obtained from 4 of the 6 G-Rex10 flasks. The quantity harvested from these 4 flasks ranged from 59.4 to 140Â 10 6 cells (Table 6 ). For patients 3613 and 3618, 5Â10 6 TIL from each of the 6 G-Rex10 flasks was seeded into a G-Rex100 flask. For patient 3625, 5Â10 6 TIL from 2 G-Rex10 flasks were each seeded into one G-Rex100 flask and 10Â10 6 TIL from the other 2 GP40 flasks were split and used to seed 4 G-Rex100 each with 5Â10 6 TIL. At the completion of REP using patient 3613 cells 22.4Â10 9 TIL were harvested, while REP using patient 3618 cells yielded 52.7Â10 9 TIL and patient 3625 cells yielded 61.0Â 10 9 TIL. The number of TIL produced by each of the 6 sets of 3 G-Rex100 flasks was similar for each patient (Fig. 7) . These results show that G-Rex100 flasks can produce sufficient quantities of TIL for clinical therapy using TIL initially cultured from tumor fragments in G-Rex10 flasks. The same G-Rex100 REP protocol was also successful in expanding TIL that were initially cultured from tumor fragments in 24-well plates. There were no significant differences in fold expansion using either TIL initially cultured from tumor fragments in 24-well plates or G-Rex10 flasks (Fig. 8) .
DISCUSSION
We describe a new and simplified method for the growth of human TIL to numbers suitable for cancer treatment using gas-permeable G-Rex flasks. We found that the entire TIL production process that typically involves 4-6 weeks of cell culture in 24-well plates, T-175 flasks and gaspermeable bags can be completed entirely in gas-permeable G-Rex flasks. This method yields 25-60Â10 9 TIL by culturing 30-40 Â10
6 tumor digest cells in 1 G-Rex10 or 30-60 pieces of tumor in 6 G-Rex10 flasks for 1-4 weeks to obtain 50-400Â 10 6 TIL followed by expansion for 7 days in 6 G-Rex100 gas-permeable flasks seeded with 30 Â 10 6 TIL and another expansion for 7 days in a total of 18 G-Rex100 flasks. The phenotype and cytokine production of TIL grown in G-Rex flasks were similar to TIL produced with 24-well plates, T-175 flasks, and bags.
The initial growth of TIL from tumor in G-Rex10 flasks has an advantage over culture in 24-well plates in that more cells were obtained in gas-permeable G-Rex flasks FIGURE 6 . Description of large-scale TIL REP using G-Rex100 flasks. For large-scale TIL REP in G-Rex100 gas-permeable flasks 5Â 10 6 TIL were cultured in 3 G-Rex100 flasks (A, B, and C) with irradiated allogeneic PBMC at a ratio of 1 to 100 in 400 mL of a 1 to 1 mixture of CM and AIM-V medium, supplemented with interleukin-2 (3000 IU/mL) and anti-CD3 (30 ng/mL) and the flasks were incubated at 371C in 5% CO 2 . On day 5, 250 mL of supernatant was removed and centrifuged. The TIL were suspended and 150 mL of a 1 to 1 mixture of CM and AIM-V media with 3000 IU/mL of IL-2 was added to the remaining 150 mL of cells. On day 7, the TIL in each G-Rex100 (A, B, and C) were suspended in the 300 mL of media present in each flask and the cell suspension was divided into three 100 mL aliquots that were used to seed 3 G-Rex100 flasks (A1, A2, and A3; B1, B2, and B3; and C1, C2, and C3). After the 100 mL cell suspension was added to each G-Rex100 flask, 150 mL of AIM-V with 5% human AB serum and IL-2 (3000 IU/mL) was added to each of the 9 G-Rex100 flasks. The G-Rex100 flasks were incubated at 371C in 5% CO 2 and on day 11,150 mL of AIM-V with IL-2 (3000 IU/mL) was added to each flask. The cells were harvested, pooled, and washed on day 14 of culture. PBMC indicates peripheral blood mononuclear cells; REP, rapid expansion protocol; TIL, tumor infiltrating lymphocyte. and it is a semiclosed system. Enough TIL for REP can be obtained from tumor digests in 1 G-Rex10 flask compared with two 24-well plates. Working with G-Rex10 flasks is also simpler and less labor intensive than working with two 24-well plates and the G-Rex10 flasks are less subject to microbial contamination than 24-well plates. We also found that TIL can be grown from tumor pieces that have not been treated with proteolytic enzymes or mechanically disrupted. This reduces the manipulation of the tumor and obviates the need for good manufacturing practice grade proteolytic enzymes and an instrument to disrupt the tissue. TIL REP in G-Rex flasks has several advantages over other REP methods. First, G-Rex flask REP requires far fewer total vessels and far less media, because these flasks support the growth of TIL at much greater cell densities than tissue culture flasks or gas-permeable bags. To produce a clinical TIL dose of 25-60 billion cells a total of 6 TIL and irradiated peripheral blood mononuclear cells at a TIL to feeder cell ratio of 1 to 100. After 7 days of culture, the TIL from each G-Rex100 was divided between 3 G-Rex100 flasks and then cultured for 7 more days. The fold expansion of TIL over 14 days is shown. TIL for REP were prepared by growth in 24-well plates from tumor fragments for 14 patients (circles) and by growth in G-Rex10 flasks from tumor fragments for 5 patients (triangles). REP indicates rapid expansion protocol. The reduced culture volume also reduces the equipment needs of the cell processing laboratory. G-Rex flask REP requires less incubator space. The REP of TIL in 15-25 three-liter bags requires the use of 2 or more incubators, but culture in 18 G-Rex100 flasks requires only 1 or 2 shelves of a standard sized incubator. The use of G-Rex flasks for REP also eliminates the need for specialized cell harvesting and concentrating devices. Many cell washing devices can be used to concentrate in a few hours the cells in the approximately 10 L cell suspension harvested from 18 G-Rex100 flasks, including instruments found in many blood banks and blood centers. One such device is the Cobe 2991 Cell Processor manufactured by Caridian BCT. However, specialized cell washers are required to process 30-40 L of cell suspensions in a few hours. Harvesting these large volumes of cell suspensions has become especially problematic as a cell harvester that has been used for many years to harvest and wash large-volume TIL suspensions is no longer commercially available.
One disadvantage of TIL culture in G-Rex flasks is that cells cannot be easily visualized. In addition, G-Rex flasks are not a closed system, but using a reduced number of G-Rex flasks compared with T-175 flasks reduces the chance of contamination. Furthermore, the manufacturer of G-Rex flasks is working to add ports to these flasks to make this a more closed system. The manufacturer of the G-Rex flasks is also working to develop a single gas-permeable flask that could take the place of 9-12 G-Rex100 flasks. Preliminary testing of a prototype vessel with a 650 cm 2 gas-permeable membrane and a capacity of approximately 5 L showed that the vessel could produce 20-25Â10 9 TIL using an initial seeding number of 10Â10 6 TIL. TIL REP using G-Rex100 flasks also requires fewer media changes. In T-175 flask/bag REP media is generally changed every other day, but for G-Rex100 REP media is changed every 3-4 days. The reduced need to change media reduces the risk of contamination because the flasks are entered less often.
Less labor is required for TIL growth in G-Rex flasks for several reasons. Laboratory staff must maintain fewer containers, media changes are less frequent, less media must be prepared and less volume of cell suspension that must be harvested.
Initial TIL growth and culture in G-Rex flasks also has advantages over the other methods described for TIL production. TIL REP can be performed in a single-pass perfusion, closed-system bioreactor, Aastrom. 14 However, this system is limited by the fixed design of its cell culture cassette. Because the maximum quantity of TIL that can be produced in each cassette is approximately 5 Â10 9 cells, several bioreactors would be required to produce sufficient quantities of TIL to treat 1 patient. Hollow fiber 15, 16 and WAVE bioreactors 17 have also been used for TIL REP. The WAVE bioreactor can be used for the entire REP process, 18 but the hollow fiber and Aastrom bioreactors can only be used for the later stages of REP.
Another group has used G-Rex flasks to expand Epstein-Barr virus (EBV)-specific cytotoxic lymphocytes, but these studies expanded cells from the peripheral blood rather than tumor derived cells. 19 In addition, an irradiated EBV-lymphoblastoid cell line was used as feeders to expand the EBV-specific cytotoxic lymphocytes rather than irradiated PBMCs.
In conclusion, the use of gas-permeable G-Rex flasks for initial TIL culture and REP allows for the reliable and reproducible production of TIL using fewer reagents than other methods. These improvements in TIL initial culture and REP will allow TIL production to move from highly specialized cell therapy laboratories to cell processing laboratories found at many academic health care centers that produce a range of cellular therapies. This could lead to the widespread use of TIL cells to treat patients with metastatic melanoma. This technology may also be useful for expanding autologous or allogeneic cells for adoptive immunotherapy of cancer such as natural killer cells or lymphocytes with engineered T-cell receptors.
